PDLIM2 and esophageal squamous cell carcinoma: The following multivariate analysis confirmed that total PDLIM2 expression was independently associated with better OS in ESCC patients (HR: 0.64, 95% CI: 0.43‐0.95, P = 0.03) (Table 2), after the adjustment for gender and pathologic stages.